Table 3.
Diagnosis Groups | CCSS | SEER |
---|---|---|
% Death (95% CI) | % Death (95% CI) | |
Total Patients | ||
5–10 years | 5.96 (5.92, 6.01) | 7.35 (7.22, 7.48) |
10–15 years | 3.03 (2.96, 3.10) | 3.34 (3.12, 3.55) |
15–20 years | 2.47 (2.39, 2.55) | 3.31 (3.08, 3.54) |
20+ years | 3.04 (2.97, 3.12) | 5.97 (5.79, 6.15) |
Leukemia | ||
5–10 years | 7.31 (7.19, 7.44) | 10.96 (10.58, 11.34) |
10–15 years | 2.81 (2.59, 3.03) | 4.55 (3.85, 5.26) |
15–20 years | 1.70 (1.41, 2.00) | 2.01 (0.86, 3.15) |
20+ years | 1.67 (1.37, 1.97) | 1.94 (0.71, 3.17) |
Kidney tumors | ||
5–10 years | 1.70 (0.64, 2.75) | 1.25 (0, 6.71) |
10–15 years | 0.94 (0, 2.39) | 1.00 (0, 5.87) |
15–20 years | 1.38 (0.18, 2.58) | 1.28 (0, 5.67) |
20+ years | 1.77 (0.69, 2.85) | 1.88 (0, 5.68) |
CNS | ||
5–10 years | 8.41 (8.13, 8.68) | 6.40 (5.91 6.89) |
10–15 years | 4.89 (4.49, 5.30) | 3.46 (2.72, 4.19) |
15–20 years | 3.82 (3.34, 4.30) | 4.22 (3.53, 4.91) |
20+ years | 5.45 (5.03, 5.87) | 8.02 (7.49, 8.54) |
Lymphoma | ||
5–10 years | 4.10 (3.81, 4.39) | 6.17 (5.72, 6.61) |
10–15 years | 2.90 (2.54, 3.26) | 3.64 (3.01, 4.27) |
15–20 years | 3.25 (2.90, 3.60) | 4.09 (3.46, 4.72) |
20+ years | 4.61 (4.31, 4.92) | 9.38 (8.95, 9.80) |
Neuroblastoma | ||
5–10 years | 2.91 (1.88, 3.94) | 4.34 (1.68, 7.01) |
10–15 years | 1.31 (0, 2.90) | 0.62 (0, 8.33) |
15–20 years | 0.85 (0, 2.86) | 1.27 (0, 6.77) |
20+ years | 1.43 (0, 2.99) | 1.35 (0, 6.99) |
Soft tissue sarcoma/Ewing sarcoma | ||
5–10 years | 7.01 (6.63, 7.39) | 7.11 (6.19, 8.02) |
10–15 years | 4.11 (3.57, 4.65) | 2.97 (1.39, 4.55) |
15–20 years | 3.81 (3.23, 4.40) | 3.88 (2.42, 5.34) |
20+ years | 3.22 (2.55, 3.89) | 4.44 (3.00, 5.89) |
Osteosarcoma/Other bone tumors | ||
5–10 years | 6.22 (5.44, 6.99) | 7.95 (5.16, 10.74) |
10–15 years | 3.48 (2.36, 4.60) | 4.23 (0, 8.61) |
15–20 years | 2.14 (0.65, 3.63) | 2.94 (0, 8.46) |
20+ years | 3.68 (2.53, 4.84) | 6.70 (2.93, 10.47) |